Intranasal Immunization of Mice with a Bovine Respiratory Syncytial Virus Vaccine Induces Superior Immunity and Protection Compared to Those by Subcutaneous Delivery or Combinations of Intranasal and Subcutaneous Prime-Boost Strategies

Mapletoft, John W.; Latimer, L.; Babiuk, Lorne A.; Hurk, Sylvia van Drunen Littel‐van den

doi:10.1128/cvi.00250-09

Cited by 32 publications

(19 citation statements)

References 53 publications

(55 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SC-immunisation was notably poor in comparison to SL- or IN-routes with respect to induction of systemic and mucosal IgA responses to gp140 and TT. The observation that SL- and IN-routes of immunisation proved much better than SC-immunisation with respect to specific IgA induction, both systemic and mucosal, is in agreement with previous studies [35].…”

Section: Discussionsupporting

confidence: 92%

Evaluation of TLR Agonists as Potential Mucosal Adjuvants for HIV gp140 and Tetanus Toxoid in Mice

et al. 2012

View full text Add to dashboard Cite

In the present study we investigate the impact of a range of TLR ligands and chitosan as potential adjuvants for different routes of mucosal immunisation (sublingual (SL), intranasal (IN), intravaginal (IVag) and a parenteral route (subcutaneous (SC)) in the murine model. We assess their ability to enhance antibody responses to HIV-1 CN54gp140 (gp140) and Tetanus toxoid (TT) in systemic and vaginal compartments. A number of trends were observed by route of administration. For non-adjuvanted antigen, SC>SL>IN immunisation with respect to systemic IgG responses, where endpoint titres were greater for TT than for gp140. In general, co-administration with adjuvants increased specific IgG responses where IN = SC>SL, while in the vaginal compartment IN>SL>SC for specific IgA. In contrast, for systemic and mucosal IgA responses to antigen alone SL>IN = SC. A number of adjuvants increased specific systemic IgA responses where in general IN>SL>SC immunisation, while for mucosal responses IN = SL>SC. In contrast, direct intravaginal immunisation failed to induce any detectable systemic or mucosal responses to gp140 even in the presence of adjuvant. However, significant systemic IgG responses to TT were induced by intravaginal immunisation with or without adjuvant, and detectable mucosal responses IgG and IgA were observed when TT was administered with FSL-1 or Poly I∶C. Interestingly some TLRs displayed differential activity dependent upon the route of administration. MPLA (TLR4) suppressed systemic responses to SL immunisation while enhancing responses to IN or SC immunisation. CpG B enhanced SL and IN responses, while having little or no impact on SC immunisation. These data demonstrate important route, antigen and adjuvant effects that need to be considered in the design of mucosal vaccine strategies.

show abstract

Section: Discussionsupporting

confidence: 92%

Evaluation of TLR Agonists as Potential Mucosal Adjuvants for HIV gp140 and Tetanus Toxoid in Mice

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Splenocytes were isolated as previously described [48]. Multiscreen-HA ELISPOT plates (Millipore) were coated with murine IFN-γ- or IL-5-specific monoclonal antibodies (BD PharMingen) at 2 μg/mL in sterile coating buffer.…”

Section: Methodsmentioning

confidence: 99%

Innate and Adaptive Immune Response to Pneumonia Virus of Mice in a Resistant and a Susceptible Mouse Strain

Watkiss

Shrivastava

Arsic

et al. 2013

Viruses

Self Cite

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) is the leading cause of infant bronchiolitis. The closely related pneumonia virus of mice (PVM) causes a similar immune-mediated disease in mice, which allows an analysis of host factors that lead to severe illness. This project was designed to compare the immune responses to lethal and sublethal doses of PVM strain 15 in Balb/c and C57Bl/6 mice. Balb/c mice responded to PVM infection with an earlier and stronger innate response that failed to control viral replication. Production of inflammatory cyto- and chemokines, as well as infiltration of neutrophils and IFN-γ secreting natural killer cells into the lungs, was more predominant in Balb/c mice. In contrast, C57Bl/6 mice were capable of suppressing both viral replication and innate inflammatory responses. After a sublethal infection, PVM-induced IFN-γ production by splenocytes was stronger early during infection and weaker at late time points in C57Bl/6 mice when compared to Balb/c mice. Furthermore, although the IgG levels were similar and the mucosal IgA titres lower, the virus neutralizing antibody titres were higher in C57Bl/6 mice than in Balb/c mice. Overall, the difference in susceptibility of these two strains appeared to be related not to an inherent T helper bias, but to the capacity of the C57Bl/6 mice to control both viral replication and the immune response elicited by PVM.

show abstract

“…For optimal induction of mucosal immune responses, several studies have suggested that vaccines should be administered through mucosal routes (3,20). However, other studies have demonstrated that vaccines given parentally can also induce mucosal antibody responses in certain settings (21,22).…”

mentioning

confidence: 99%

Common Features of Mucosal and Peripheral Antibody Responses Elicited by Candidate HIV-1 Vaccines in Rhesus Monkeys

Stephenson

Kang

et al. 2014

J Virol

View full text Add to dashboard Cite

bHuman immunodeficiency virus type 1 (HIV-1) vaccines that elicit protective antibody responses at mucosal sites would be highly desirable. Here, we report that intramuscular immunization of candidate HIV-1 vaccine vectors and purified Env proteins elicited potent and durable humoral immune responses in colorectal mucosa in rhesus monkeys. The kinetics, isotypes, functionality, and epitope specificity of these mucosal antibody responses were similar to those of peripheral responses in serum. These data suggest a close immunological relationship between mucosal and systemic antibody responses following vaccination in primates. Human mucosal surfaces represent the major portal of entry for human immunodeficiency virus type 1 (HIV-1) (1). Thus, a prophylactic vaccine will likely need to elicit protective antibody responses at mucosal sites of virus exposure. However, mucosal humoral immune responses following vaccination are poorly characterized. The RV144 clinical trial suggested that vaccine-elicited HIV-1 envelope (Env)-specific humoral immune responses may have contributed to the partial protection observed for vaccinees (2), but mucosal immune responses were not assessed in that trial. In contrast, previous studies have shown that immunization with peptide, DNA, protein, or attenuated bacterial or viral vector-based vaccines through parental or mucosal routes may elicit antigen-specific humoral immune responses at mucosal sites in mice, nonhuman primates, and humans (3-7). However, the characteristics, functionality, and epitope specificity of vaccine-elicited mucosal antibody responses have not been fully explored. Moreover, whether mucosal antibody responses reflect distinct populations compared with those for peripheral antibody responses remains to be determined. We therefore assessed the magnitude, durability, isotype, neutralizing activity, and epitope specificity of mucosal and peripheral antibody responses in rhesus monkeys elicited by adenovirus (Ad) vector-based and proteinbased HIV-1 vaccine candidates.We first collected blood and colorectal mucosal secretions using Weck-Cel sponges from 8 healthy adult rhesus monkeys. Using sera and mucosal secretions eluted from Weck-Cel sponges (8), we assessed the amount of total IgG and IgA (monkey IgG/IgA enzyme-linked immunosorbent assay [ELISA] kit; Alpha Diagnostic). The average volume of eluates from 8 unused sponges was used as the elution buffer volume, and a dilution factor was calculated according to the volume of eluate for each sample: dilution factor ϭ experiment sponge eluate volume/(experiment sponge eluate volume Ϫ unused sponge eluate volume). The dilution factor was used to calculate total IgG and IgA as well as titers

show abstract

Intranasal Immunization of Mice with a Bovine Respiratory Syncytial Virus Vaccine Induces Superior Immunity and Protection Compared to Those by Subcutaneous Delivery or Combinations of Intranasal and Subcutaneous Prime-Boost Strategies

Cited by 32 publications

References 53 publications

Evaluation of TLR Agonists as Potential Mucosal Adjuvants for HIV gp140 and Tetanus Toxoid in Mice

Evaluation of TLR Agonists as Potential Mucosal Adjuvants for HIV gp140 and Tetanus Toxoid in Mice

Innate and Adaptive Immune Response to Pneumonia Virus of Mice in a Resistant and a Susceptible Mouse Strain

Common Features of Mucosal and Peripheral Antibody Responses Elicited by Candidate HIV-1 Vaccines in Rhesus Monkeys

Contact Info

Product

Resources

About